Table 3.

Estimated RSV-associated Health Outcomes and Costs, With and Without RSVIG or Palivizumab Prophylaxis, for a Hypothetic Cohort of 1000 Infants With Gestation ≤32 Weeks, an Oxygen Requirement in the NICU of ≥28 Days, and NICU Discharge Between September and November (Group A)*

No ProphylaxisRSVIGPalivizumab
Number of infants in cohort1000 1000 1000
Acquisition cost of prophylaxis0 3 000 000 2 700 000
Administration cost of prophylaxis0 840 000 100 000
Work loss cost of prophylaxis0 176 000 44 000
Number of infants hospitalized for RSV246 128 111
Direct cost of hospitalizations2 091 492 1 087 576 941 171
Direct cost of prehospitalization visit48 585 25 264 21 863
Work loss cost of hospitalization88 757 46 154 39 941
Infant deaths2.951.541.33
Life-years lost (undiscounted)221.99115.4499.9 
Life-years lost (discounted) 88.0645.7939.63
Total cost2 228 834 5 174 994 3 846 975
Incremental cost of prophylaxis2 946 160 1 618 141
Cases averted118 135
Life-years saved (undiscounted)106.56122.09
Life-years saved (discounted)42.2748.43
Cost per case averted25 000 12 000
Cost per life-year saved (discounted)70 000 33 000
  • * All costs are in 1995 dollars.

  • Discounting at 3% per year.